Chemed Co. (NYSE:CHE) Stock Position Raised by Arizona State Retirement System

Posted by Defense World Staff on May 10th, 2023

Arizona State Retirement System lifted its position in Chemed Co. (NYSE:CHE – Get Rating) by 3.4% in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 4,205 shares of the company’s stock after acquiring an additional 137 shares during the quarter. Arizona State Retirement System’s holdings in Chemed were worth $2,146,000 as of its most recent filing with the SEC.

Other hedge funds have also made changes to their positions in the company. U.S. Capital Wealth Advisors LLC purchased a new stake in shares of Chemed in the 4th quarter valued at approximately $26,000. IFP Advisors Inc lifted its position in shares of Chemed by 13.7% in the 3rd quarter. IFP Advisors Inc now owns 274 shares of the company’s stock valued at $37,000 after acquiring an additional 33 shares in the last quarter. Canada Pension Plan Investment Board purchased a new stake in shares of Chemed in the 1st quarter valued at approximately $46,000. Quadrant Capital Group LLC lifted its position in Chemed by 29.2% in the 3rd quarter. Quadrant Capital Group LLC now owns 115 shares of the company’s stock worth $50,000 after buying an additional 26 shares in the last quarter. Finally, Wipfli Financial Advisors LLC purchased a new stake in Chemed in the 3rd quarter worth approximately $54,000. Hedge funds and other institutional investors own 91.12% of the company’s stock.

Chemed Stock Performance

Shares of CHE opened at $546.34 on Wednesday. The company’s fifty day moving average is $538.10 and its 200-day moving average is $515.11. Chemed Co. has a 12 month low of $430.16 and a 12 month high of $570.17. The firm has a market cap of $8.21 billion, a price-to-earnings ratio of 34.38, a price-to-earnings-growth ratio of 3.04 and a beta of 0.54. The company has a quick ratio of 0.89, a current ratio of 0.93 and a debt-to-equity ratio of 0.02.

Chemed (NYSE:CHE – Get Rating) last posted its earnings results on Friday, February 24th. The company reported $5.39 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.30 by $0.09. Chemed had a net margin of 11.07% and a return on equity of 37.83%. The business had revenue of $546.65 million for the quarter, compared to analyst estimates of $546.60 million. During the same period last year, the business posted $5.25 EPS. Chemed’s revenue was up 1.0% compared to the same quarter last year. Equities analysts expect that Chemed Co. will post 20.57 EPS for the current fiscal year.

Chemed Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, March 17th. Investors of record on Monday, February 27th were issued a dividend of $0.38 per share. This represents a $1.52 dividend on an annualized basis and a yield of 0.28%. The ex-dividend date of this dividend was Friday, February 24th. Chemed’s dividend payout ratio is currently 9.57%.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the stock. StockNews.com assumed coverage on shares of Chemed in a research report on Thursday, March 16th. They issued a “buy” rating for the company. Royal Bank of Canada increased their target price on shares of Chemed from $587.00 to $610.00 in a research report on Monday, May 1st. Finally, Oppenheimer increased their target price on shares of Chemed from $580.00 to $610.00 in a research report on Friday, April 28th.

Insider Buying and Selling at Chemed

In other news, CEO Kevin J. Mcnamara sold 2,000 shares of the business’s stock in a transaction on Thursday, March 9th. The shares were sold at an average price of $507.32, for a total value of $1,014,640.00. Following the sale, the chief executive officer now owns 121,613 shares of the company’s stock, valued at $61,696,707.16. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In related news, CEO Kevin J. Mcnamara sold 2,000 shares of the company’s stock in a transaction dated Thursday, March 9th. The shares were sold at an average price of $507.32, for a total transaction of $1,014,640.00. Following the completion of the sale, the chief executive officer now owns 121,613 shares of the company’s stock, valued at $61,696,707.16. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO David Patrick Williams sold 4,000 shares of the firm’s stock in a transaction that occurred on Monday, March 20th. The shares were sold at an average price of $523.25, for a total transaction of $2,093,000.00. Following the completion of the transaction, the chief financial officer now owns 20,443 shares of the company’s stock, valued at approximately $10,696,799.75. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 13,000 shares of company stock valued at $6,883,810. 3.80% of the stock is currently owned by corporate insiders.

Chemed Company Profile

(Get Rating)

Chemed Corp. engages in the provision of healthcare and maintenance services. It operates through the VITAS and Roto-Rooter segments. The VITAS segment offers hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers.